{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:12Z","timestamp":1792783332673,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2024 Tianjin Comprehensive Clinical Evaluation of Drugs Project","award":["TZH-2024-002"],"award-info":[{"award-number":["TZH-2024-002"]}]},{"name":"Pilot study on the standardization of comprehensive clinical evaluation of drugs","award":["PJC202410"],"award-info":[{"award-number":["PJC202410"]}]},{"name":"2023 Tianjin Pharmacy Young and Middle-aged Research Programs","award":["TJYX2023-03"],"award-info":[{"award-number":["TJYX2023-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11596-025-00120-5","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T07:33:45Z","timestamp":1759908825000},"page":"1138-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness"],"prefix":"10.1007","volume":"45","author":[{"given":"Li-li","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-xiang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-tian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"120_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2200","volume":"370","author":"Y Shi","year":"2020","unstructured":"Shi Y, Zheng M. Hepatitis B Virus Persistence and Reactivation.\u00a0BMJ, 2020,370:m2200.","journal-title":"BMJ"},{"issue":"2","key":"120_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s12072-021-10137-2","volume":"15","author":"A Koffas","year":"2021","unstructured":"Koffas A, Kumar M, Gill US, et al. Chronic hepatitis B: the demise of the 'inactive carrier' phase. Hepatol Int. 2021;15(2):290\u2013300.","journal-title":"Hepatol Int."},{"key":"120_CR3","unstructured":"World Health Organization. Urgent health challenges for the next decade. Available online:\u00a0https:\/\/www.who.int\/news-room\/photo-story\/photo-story-detail\/urgent-health-challenges-for-the-next-decade. Accessed 13 January 2020."},{"issue":"4","key":"120_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.cld.2021.06.002","volume":"25","author":"SE Dekker","year":"2021","unstructured":"Dekker SE, Green EW, Ahn J. Treatment and Prevention of Acute Hepatitis B Virus. Clin Liver Dis. 2021;25(4):711\u2013724.","journal-title":"Clin Liver Dis."},{"issue":"12","key":"120_CR5","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","volume":"72","author":"Z Liu","year":"2023","unstructured":"Liu Z, Lin C, Mao X, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023;72(12):2354\u20132363.","journal-title":"Gut."},{"key":"120_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104386","volume":"126","author":"SJ Walker","year":"2024","unstructured":"Walker SJ, Shrestha LB, Lloyd AR, et al. Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit. Int J Drug Policy, 2024,126:104386.","journal-title":"Int J Drug Policy"},{"key":"120_CR7","unstructured":"World Health Organization. Global Hepatitis Report, 2017. Available online:\u00a0https:\/\/www.who.int\/publications\/i\/item\/9789241565455. Accessed 19 April 2017."},{"issue":"2","key":"120_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12072-008-9061-6","volume":"2","author":"N Leung","year":"2008","unstructured":"Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int. 2008;2(2):163\u2013178.","journal-title":"Hepatol Int."},{"issue":"6","key":"120_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.4254\/wjh.v16.i6.900","volume":"16","author":"YP Li","year":"2024","unstructured":"Li YP, Liu CR, He L, et al. Hepatitis B cure: Current situation and prospects. World J Hepatol. 2024;16(6):900\u2013911.","journal-title":"World J Hepatol."},{"issue":"4","key":"120_CR10","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","volume":"139","author":"G Woo","year":"2010","unstructured":"Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218\u20131229.","journal-title":"Gastroenterology."},{"issue":"10","key":"120_CR11","first-page":"893","volume":"32","author":"ZH Liu","year":"2024","unstructured":"Liu ZH, Jin QL, Zhang YX, et al. Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase III multicenter, randomized controlled trial. Zhonghua Gan Zang Bing Za Zhi (Chinese), 2024;32(10):893\u2013903.","journal-title":"Zhonghua Gan Zang Bing Za Zhi (Chinese)"},{"issue":"44","key":"120_CR12","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","volume":"29","author":"WT Peng","year":"2023","unstructured":"Peng WT, Jiang C, Yang FL, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol. 2023;29(44):5907\u20135918.","journal-title":"World J Gastroenterol."},{"issue":"6","key":"120_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/jvh.13500","volume":"28","author":"MS Farag","year":"2021","unstructured":"Farag MS, Fung S, Tam E, et al. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. J Viral Hepat. 2021;28(6):942\u2013950.","journal-title":"J Viral Hepat."},{"issue":"5","key":"120_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s12072-021-10234-2","volume":"15","author":"HW Lee","year":"2021","unstructured":"Lee HW, Cho YY, Lee H, et al. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int. 2021;15(5):1083\u20131092.","journal-title":"Hepatol Int."},{"issue":"9","key":"120_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1134\u20131149.","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"120_CR16","doi-asserted-by":"publisher","first-page":"135965352412842","DOI":"10.1177\/13596535241284226","volume":"29","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Xu J, Liu D, et al. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Antivir Ther. 2024;29(5):13596535241284226.","journal-title":"Antivir Ther."},{"issue":"1","key":"120_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/apt.16668","volume":"55","author":"S Lens","year":"2022","unstructured":"Lens S, Pocurull A. Editorial: the three tenors in HBV - TDF, TAF and now TMF. Aliment Pharmacol Ther. 2022;55(1):120.","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"120_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14029","volume":"32","author":"X Rong","year":"2025","unstructured":"Rong X, Yang G, Xu Y, et al. Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First-Time HBV-Related Decompensated Cirrhosis. J Viral Hepat. 2025;32(4):e14029.","journal-title":"J Viral Hepat."},{"key":"120_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fphar.2022.932934","volume":"13","author":"X Hong","year":"2022","unstructured":"Hong X, Cai Z, Zhou F, et al. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Front Pharmacol. 2022;13:932\u2013934.","journal-title":"Front Pharmacol."},{"key":"120_CR20","doi-asserted-by":"publisher","first-page":"1165990","DOI":"10.3389\/fphar.2023.1165990","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zhou J, Li Y, et al. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study. Front Pharmacol. 2023;14:1165990.","journal-title":"Front Pharmacol."},{"key":"120_CR21","doi-asserted-by":"publisher","first-page":"1545108","DOI":"10.3389\/fphar.2025.1545108","volume":"16","author":"X Qiu","year":"2025","unstructured":"Qiu X, Yin Y, Zhang S, et al. Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study. Front Pharmacol. 2025;16:1545108.","journal-title":"Front Pharmacol."},{"issue":"11","key":"120_CR22","first-page":"976","volume":"32","author":"RY Chen","year":"2024","unstructured":"Chen RY, Lyu XY, Huang S, et al. Comparative therapeutic efficacy of tenofovir amibufenamide versus tenofovir alafenamide in the treatment of patients with chronic hepatitis B: a real-world single- center study. Zhonghua Gan Zang Bing Za Zhi (Chinese). 2024;32(11):976\u2013983.","journal-title":"Zhonghua Gan Zang Bing Za Zhi (Chinese)"},{"issue":"3","key":"120_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.14218\/JCTH.2022.00167","volume":"10","author":"X Zhao","year":"2022","unstructured":"Zhao X, Li M, Wang H, et al. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. J Clin Transl Hepatol. 2022;10(3):420\u2013428.","journal-title":"J Clin Transl Hepatol."},{"issue":"4","key":"120_CR24","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u20131599.","journal-title":"Hepatology."},{"issue":"3","key":"120_CR25","first-page":"252","volume":"31","author":"QJ Sheng","year":"2023","unstructured":"Sheng QJ, Han C, Li YW, et al. Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues. Zhonghua Gan Zang Bing Za Zhi (Chinese), 2023;31(3):252\u2013257.","journal-title":"Zhonghua Gan Zang Bing Za Zhi (Chinese)"},{"issue":"1","key":"120_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12876-025-03600-z","volume":"25","author":"Q Wei","year":"2025","unstructured":"Wei Q, Zhao J. Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients. BMC Gastroenterol. 2025;25(1):68.","journal-title":"BMC Gastroenterol."},{"key":"120_CR27","doi-asserted-by":"publisher","first-page":"7689981","DOI":"10.1155\/cjgh\/7689981","volume":"2025","author":"Y Diao","year":"2025","unstructured":"Diao Y, Zeng Y, Huang Z, et al. Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol. 2025;2025:7689981.","journal-title":"Can J Gastroenterol Hepatol."},{"issue":"3","key":"120_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4103\/1319-3767.157558","volume":"21","author":"HM Yu","year":"2015","unstructured":"Yu HM, Kwon SY, Kim J, et al. Virologic response and safety of tenofovir versus entecavir in treatment-na\u00efve chronic Hepatitis B patients. Saudi J Gastroenterol. 2015;21(3):146\u2013151.","journal-title":"Saudi J Gastroenterol."},{"key":"120_CR29","first-page":"204993612098595","volume":"8","author":"L Roade","year":"2021","unstructured":"Roade L, Riveiro-Barciela M, Esteban R, et al. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis, 2021,8:2049936120985954.","journal-title":"Ther Adv Infect Dis"},{"key":"120_CR30","first-page":"72","volume":"25","author":"M Wang","year":"2023","unstructured":"Wang M. Efficacy Analysis of Tenofovir Alafenamide in the Treatment of HBeAg-Positive Chronic Hepatitis B.\u00a0Mod Med J China (Chinese). 2023;25:72\u201375.","journal-title":"Mod Med J China."},{"key":"120_CR31","first-page":"73","volume":"21","author":"XY Lv","year":"2023","unstructured":"Lv XY, Chen RY, Pan YJ, et al. Early efficacy and safety study of emtinofovir in the treatment of patients with hepatitis B virus-associated cirrhosis.\u00a0J Yanan Univ (Chinese). 2023;21:73\u201382.","journal-title":"J Yanan Univ (Med Sci Ed)"},{"issue":"5","key":"120_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/MNH.0000000000000907","volume":"32","author":"S Singh","year":"2023","unstructured":"Singh S. Medication safety in chronic kidney disease. Curr Opin Nephrol Hypertens. 2023;32(5):434\u2013438.","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"3","key":"120_CR33","first-page":"649","volume":"11","author":"Z Liu","year":"2023","unstructured":"Liu Z, Jin Q, Zhang Y, et al. 96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. J Clin Transl Hepatol, 2023,11(3):649\u2013660.","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"120_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jhep.2009.07.015","volume":"51","author":"GM Dusheiko","year":"2009","unstructured":"Dusheiko GM. Cost-effectiveness of oral treatments for chronic hepatitis B. J Hepatol. 2009;51(4):623\u2013625.","journal-title":"J Hepatol."},{"issue":"4","key":"120_CR35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2007.07.016","volume":"47","author":"A Rajendra","year":"2007","unstructured":"Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. J Hepatol. 2007;47(4):608\u2013617.","journal-title":"J Hepatol."},{"key":"120_CR36","doi-asserted-by":"publisher","first-page":"1503711","DOI":"10.3389\/fendo.2025.1503711","volume":"16","author":"QM Tu","year":"2025","unstructured":"Tu QM, Jin HM, Yang XH. Lipid abnormality in diabetic kidney disease and potential treatment advancements. Front Endocrinol (Lausanne). 2025;16:1503711.","journal-title":"Front Endocrinol (Lausanne)."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00120-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00120-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00120-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:03:59Z","timestamp":1762290239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00120-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["120"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00120-5","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the\u00a0Declaration of Helsinki\u00a0and approved by the Ethics Committee of Tianjin University Central Hospital (Protocol Code: IRB2024-074\u201301). Informed consent was obtained from all subjects involved in the study, and written informed consent was specifically obtained from the patients for the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}